Key Company Facts

• In January 2007, the Company employs 9 persons.

• In 2006, Genesodi is now part of Genoscience : Predict Search, innovative technology will allow Genoscience to generate cash to invest in R&D.

• In 2006, our family of protease inhibitors shows an activity under 1micromolar and we plan an Antiviral activity, at 0,1 micromolar.
  

• In 2005, we acquired a Patent from Inserm for the HCVpp test.

• In 2005, in house development of chemical and biological part and cellular testing.

• In 2004, Genoscience started a program on HCV entry inhibitors based on a drug design approach thanks to its experience.

• In 2004, a family of HIV entry peptide inhibitors has been discovered. The peptides exhibited a mechanism of action that is different from other drugs. The family of compounds therefore represents a substitute to the current anti-HIV treatments. A patent has been filled out.

• In 2003, an internal platform of testing was created to accelerate the processes of HCV IP development at a low molar level.

• In 2002, Genoscience signed a collaborative partnership with the pharmaceutical company Gilead in the field of HIV drug resistance, with Tenofovir®.

• At the end of 2001, a HCV protease inhibitor drug discovery serine protease program started with an external outsourcing of chemical synthesis.

• In mid 2001, Genoscience concluded the acquisition of GenMol and developed specific applications in disease management and drug discovery. Genoscience out-source research and development when possible and appropriate. Its organisation allowed Genoscience to optimize resource allocations and to make quick decisions on the priorities of the development program.